Phase 2 N=14 A Double-blind Study to Evaluate the Safety of Glutamic Acid Decarboxylase Gene Transfer in Parkinson's Participants
Parkinson's Disease
Primary: Incidence of Adverse Events Related to the Treatment — 0; 1; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=24 Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-827104 in Pediatric Subjects With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep
Epileptic Encephalopathy · Continuous Spike and Wave During Sleep
Primary: Ratio of Spike-Wave Index (SWI) During First Hour of Nonrapid Eye Movement (NREM) Sleep at Week 6 — -0.02; 0.01 Log-transformed ratio — p=0.4326
Phase 2 N=36 Maximal Use Study of Tapinarof Cream, 1% in Pediatric Subjects With Extensive Atopic Dermatitis
Atopic Dermatitis
Primary: Number of Participants That Experienced Adverse Events (AEs) and Serious Adverse Events (SAEs) — 8; 0 Participants
Phase 2 N=33 A Study to Evaluate Organ Level Uptake Repeatability of 124I AT-01 in Subjects With Systemic Amyloidosis
Amyloidosis
Primary: Within-Participant Coefficient of Variation [wCV] Associated With the Quantification (SUVmax) of Radioactivity Associated With Organ-Level Radiotracer Uptake — 14.58…
Phase 2 N=64 Low Molecular Weight Heparin or no Treatment Following Cesarean Delivery
Thromboembolism
Primary: Rate of Eligible Individuals Enrolled and Retained Through Full Study Procedures — 694; 611; 64; 61 participants
Phase 2 N=171 GLS-5310 Vaccine for the Prevention of SARS-CoV-2 (COVID-19)
SARS-CoV-2
Primary: Number of Serious Adverse Events — 0; 0; 0; 0 serious adverse events
Phase 2 N=3 Suprachoroidal Sustained-Release OXU-001 Compared to Intravitreal Ozurdex® in the Treatment of Diabetic Macular Edema
Diabetic Macular Edema
Primary: Frequency and Severity of Ocular and Systemic Treatment Emergent Adverse Events, Serious Adverse Events, and Adverse Events of Special Interest — 0; 2; 1; 2 Participants
Phase 2 N=54 A Study to Evaluate the Safety and Efficacy of Cotadutide Given by Subcutaneous Injection in Adult Participants With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis
Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis
Primary: Number of Participants With Adverse Events (AEs). — 16; 16; 13 Participants
Phase 2 N=64 Phase 2 Study of Rivaroxaban Reversal by Ciraparantag as Measured by WBCT
Healthy
Primary: Subjects Achieving Complete Reversal of Anticoagulation (WBCT is ≤ 110% of Baseline) — 3; 7; 11; 11 Participants
Phase 2 N=23 Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL)
Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic · Chronic Lymphocytic Leukemia · Small Lymphocytic Leukemia
Primary: Participants With Complete Remission (CR) at 24 Months — 3 Participants
Phase 2 N=49 Phase 2 Study of Apixaban Reversal by Ciraparantag as Measured by WBCT
Healthy
Primary: Subjects Achieving Complete Reversal of Anticoagulation (WBCT is ≤ 110% of Baseline) — 2; 9; 12; 12 Participants
Phase 2 N=15 Pilot Study of Psilocybin-Assisted Therapy for Demoralization in Patients Receiving Hospice Care
Hospice · Psilocybin · Demoralization
Primary: Number of Participants Screened Per Study Period — 4607 participants
Phase 2 N=381 An Efficacy and Safety Study of Mitiperstat (AZD4831) (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPD.
Chronic Obstructive Pulmonary Disease (COPD)
Primary: To Evaluate the Effect of Mitiperstat (AZD4831) as Compared to Placebo on the Time to First COPD Composite Exacerbation (CompEx) Event in Patients With Moderate to…
Phase 2 N=152 A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery
Breast Cancer
Primary: Percent Reduction in Ki-67 Expression From Baseline to Day 15 in Tumor Biopsies — 71.4; 72.9 Percent reduction
Phase 2 N=187 Study of Anti-Malarials in Incomplete Lupus Erythematosus
Systemic Lupus Erythematosus
Primary: SLICC Score — 62; 56; 46; 41 participants — p=0.72